Nintedanib Accordpharma (Nintedanib)

Nintedanib blocks multiple receptor tyrosine kinases—VEGFR, PDGFR and FGFR—thereby inhibiting signalling pathways that promote fibroblast proliferation, angiogenesis and extracellular matrix deposition. This dual antifibrotic and anti‑angiogenic activity helps slow tissue scarring and tumor growth.

The specific dose and dosing schedule of Nintedanib Accordpharma are determined by the treating physician based on the patient’s condition, renal and hepatic function, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of Nintedanib during pregnancy or lactation has not been established. It is generally advised to avoid use in pregnant or nursing women unless the potential benefit justifies the potential risk, and a healthcare professional should be consulted.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative for idiopathic pulmonary fibrosis is pirfenidone, another antifibrotic agent. While both aim to slow disease progression, Nintedanib targets a broader range of tyrosine kinases, potentially offering benefits in patients with concomitant vascular involvement, whereas pirfenidone’s mechanism focuses on oxidative stress and cytokine modulation.

Nintedanib should be stored at ambient temperature, preferably below 25 °C, in its original container to protect it from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or direct sunlight.

Nintedanib is taken orally, usually with food to lessen gastrointestinal discomfort. Tablets are swallowed whole with a glass of water and should be taken at the same time each day as directed by the prescriber.

Serious risks include liver injury (elevated transaminases or hepatitis), severe bleeding events, and arterial thrombotic complications such as myocardial infarction. Patients should report signs of jaundice, unusual bruising, or chest pain to their healthcare provider promptly.

Nintedanib is contraindicated in patients with known hypersensitivity to the drug, those with severe hepatic impairment, and individuals taking strong CYP3A4 inducers that could markedly reduce its efficacy. Caution is also advised for patients with active bleeding disorders or uncontrolled cardiovascular disease.